AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23398636 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard diet + 6 × 60 ml/day of Pro-Cal (60 ml = 200 kcal + 4 g protein)
Number of subjects: 55
Study 23398636 — intervention group
Group type: COMPARATOR
Intervention: Standard diet alone
Number of subjects: 55
Study 21311842 — intervention group
Group type: EXPERIMENTAL
Intervention: Care provided by a hospital-based specialised asthma nurse
Number of subjects: 107
Study 21311842 — intervention group
Group type: COMPARATOR
Intervention: General practitioner (GP) care
Number of subjects: 107
Study 21311842 — intervention group
Group type: COMPARATOR
Intervention: Paediatrician care
Number of subjects: 107
Study 21311842 — intervention group
Group type: COMPARATOR
Intervention: Specialised asthma nurse care
Number of subjects: 107
Study 19845100 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream (lidocaine 2.5% plus prilocaine 2.5%) applied daily
Number of subjects: 65
Study 19845100 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone acetate 40 mg injection
Number of subjects: 65
Study 16757756 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation with porcine small intestine mucosa
Number of subjects: 30
Study 16757756 — intervention group
Group type: COMPARATOR
Intervention: No augmentation (Control)
Number of subjects: 30
Study 16757756 — intervention group
Group type: EXPERIMENTAL
Intervention: Healed repair
Number of subjects: 30
Study 16757756 — intervention group
Group type: EXPERIMENTAL
Intervention: Failed repair
Number of subjects: 30
Study 15004874 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg qd) for 12 weeks
Number of subjects: 18
Study 15004874 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 children aged 11 to 15 with no medical or psychiatric illnesses)
Number of subjects: 18
Study 11765381 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) intervention
Number of subjects: 17
Study 9262274 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Analgesia (PCA) with fentanyl
Number of subjects: 81
Study 9262274 — intervention group
Group type: COMPARATOR
Intervention: Physician-administered fentanyl
Number of subjects: 81
Study 8418715 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 143
Study 8418715 — intervention group
Group type: COMPARATOR
Intervention: Inhaled anesthetics
Number of subjects: 143
Study 8418715 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 143
Study 3535594 — intervention group
Group type: EXPERIMENTAL
Intervention: RHZ regimen (isoniazid and rifampin with pyrazinamide)
Number of subjects: 358
Study 3535594 — intervention group
Group type: EXPERIMENTAL
Intervention: RHE regimen (isoniazid and rifampin with ethambutol)
Number of subjects: 358
Study 3535594 — intervention group
Group type: COMPARATOR
Intervention: SHE regimen (streptomycin, isoniazid, and ethambutol for 6 months followed by isoniazid and ethambutol for an additional 6 months)
Number of subjects: 358
Study 3535594 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment regimens
Number of subjects: 358
Study 2786899 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.i.d.
Number of subjects: 110
Study 2786899 — intervention group
Group type: COMPARATOR
Intervention: Placebo b.i.d.
Number of subjects: 110
Study 30025665 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Therapy (MT)
Number of subjects: 50
Study 29041941 — intervention group
Group type: EXPERIMENTAL
Intervention: Komboni Housewives intervention (community events, health clinics, radio)
Number of subjects: 0
Study 29041941 — intervention group
Group type: EXPERIMENTAL
Intervention: Komboni Housewives intervention
Number of subjects: 0
Study 25319879 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy with defibrillator (CRT-D)
Number of subjects: 97
Study 23336504 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) intervention with Standard Health Care Advice (SHCA)
Number of subjects: 510
Study 23336504 — intervention group
Group type: COMPARATOR
Intervention: Standard Health Care Advice (SHCA)
Number of subjects: 510
Study 21659318 — intervention group
Group type: EXPERIMENTAL
Intervention: Decoupling (DC) technique
Number of subjects: 72
Study 21659318 — intervention group
Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 72
Study 18042987 — intervention group
Group type: EXPERIMENTAL
Intervention: 500‐microg F/g (NaF) dentifrice
Number of subjects: 120
Study 18042987 — intervention group
Group type: COMPARATOR
Intervention: 1,100‐microg F/g dentifrice
Number of subjects: 120
Study 16209659 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine (0.6 mg)
Number of subjects: 15
Study 16209659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 12547992 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (5 microg x kg(-1) x min(-1))
Number of subjects: 15
Study 12547992 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 15
Study 11137410 — intervention group
Group type: EXPERIMENTAL
Intervention: New intubation method with TV monitoring
Number of subjects: 90
Study 11137410 — intervention group
Group type: COMPARATOR
Intervention: Conventional intubation using rigid laryngoscope
Number of subjects: 90
Study 8659651 — intervention group
Group type: EXPERIMENTAL
Intervention: Saving Lives Program cities
Number of subjects: 54577
Study 1390375 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5mg intrathecal morphine with 3 mls of 0.5% intrathecal bupivacine
Number of subjects: 24
Study 1390375 — intervention group
Group type: COMPARATOR
Intervention: 3 mls of 0.5% bupivacine with normal saline
Number of subjects: 24
Study 4005097 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous monitoring of blood glucose concentration
Number of subjects: 12
Study 4005097 — intervention group
Group type: COMPARATOR
Intervention: Frequent intermittent sampling
Number of subjects: 12
Study 30079637 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) + 5000 ppm sodium fluoride (GLASER)
Number of subjects: 25
Study 30079637 — intervention group
Group type: COMPARATOR
Intervention: Placebo (laser tip without emission of light) + 5000 ppm sodium fluoride (GPLACEBO)
Number of subjects: 25
Study 27212226 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic group cognitive behavioral therapy (TGCBT) for anxiety over 12 weeks
Number of subjects: 151
Study 25016974 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 416
Study 25016974 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic Therapy
Number of subjects: 416
Study 25016974 — intervention group
Group type: COMPARATOR
Intervention: Wait-list Control
Number of subjects: 416
Study 22873492 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin plus clavulanic acid
Number of subjects: 89
Study 22873492 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium benzoate
Number of subjects: 89
Study 22873492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 22873492 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin plus clavulanic acid vs Sodium benzoate
Number of subjects: 89
Study 21049208 — intervention group
Group type: EXPERIMENTAL
Intervention: Group PK (0.15 mg/kg ketamine + 80 ml 0.5% prilocaine)
Number of subjects: 40
Study 21049208 — intervention group
Group type: COMPARATOR
Intervention: Group P (80 ml 0.5% prilocaine)
Number of subjects: 40
Study 18211452 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Laryngoscope
Number of subjects: 49
Study 18211452 — intervention group
Group type: COMPARATOR
Intervention: Standard Macintosh Laryngoscope
Number of subjects: 49
Study 15816475 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b/ribavirin combination therapy
Number of subjects: 0
Study 15816475 — intervention group
Group type: COMPARATOR
Intervention: Interferon alpha-2b monotherapy
Number of subjects: 0
Study 11443628 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusional cyclophosphamide (187.5 mg/m² per day), doxorubicin (12.5 mg/m² per day), and etoposide (60 mg/m² per day) administered as second-line chemotherapy for 96 hours continuous intravenous infusion.
Number of subjects: 40
Study 10078811 — intervention group
Group type: EXPERIMENTAL
Intervention: Postischaemic cases (survived cardiac arrest)
Number of subjects: 3
Study 10078811 — intervention group
Group type: COMPARATOR
Intervention: Control cases (neurologically healthy individuals who died following an accident)
Number of subjects: 3
Study 8079928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine plus amoxycillin (500 mg three times a day for 2 weeks) and metronidazole (250 mg three times a day for 2 weeks)
Number of subjects: 48
Study 8079928 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine alone (800 mg at night for 4 weeks)
Number of subjects: 48
Study 2680816 — intervention group
Group type: EXPERIMENTAL
Intervention: Cop 1
Number of subjects: 50
Study 2680816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 786681 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous atropine sulphate (0.25, 0.40, 0.75 and 1.50 mg)
Number of subjects: 72
Study 786681 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous atropine methylnitrate (0.08, 0.13 and 0.25 mg)
Number of subjects: 72
Study 786681 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 72
Study 31976794 — intervention group
Group type: EXPERIMENTAL
Intervention: Military families with 1 ACE
Number of subjects: 5336
Study 31976794 — intervention group
Group type: EXPERIMENTAL
Intervention: Military families with 2 ACEs
Number of subjects: 5336
Study 31976794 — intervention group
Group type: EXPERIMENTAL
Intervention: Military families with 3-6 ACEs
Number of subjects: 5336
Study 31976794 — intervention group
Group type: EXPERIMENTAL
Intervention: Military families attempting suicide
Number of subjects: 5336
Study 30755234 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate Milk (CM)
Number of subjects: 103
Study 30755234 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate supplements (CHO)
Number of subjects: 103
Study 27436450 — intervention group
Group type: EXPERIMENTAL
Intervention: GPS needle-tracking system
Number of subjects: 220
Study 27436450 — intervention group
Group type: COMPARATOR
Intervention: Multiplanar ultrasound system
Number of subjects: 220
Study 27436450 — intervention group
Group type: COMPARATOR
Intervention: 2D imaging
Number of subjects: 220
Study 26913493 — intervention group
Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 54
Study 26913493 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis ssp. lactis Bb12 (ATCC 27536) chewing gum
Number of subjects: 54
Study 26913493 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus LGG (ATCC 53103), Bifidobacterium longum 46 (DSM 14583) and Bifidobacterium longum 2C (DSM 14579) chewing gum
Number of subjects: 54
Study 24103190 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 327
Study 24103190 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-directive counselling
Number of subjects: 327
Study 24103190 — intervention group
Group type: COMPARATOR
Intervention: Usual GP care
Number of subjects: 327
Study 22322458 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief eclectic psychotherapy
Number of subjects: 140
Study 22322458 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR
Number of subjects: 140
Study 19569007 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (n=20)
Number of subjects: 40
Study 19569007 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=20)
Number of subjects: 40
Study 17590218 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide (100 mg twice a day)
Number of subjects: 44
Study 17590218 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib (200 mg once a day)
Number of subjects: 44
Study 14733608 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg plus IFNalpha (400 mg/kg each day for 5 days, then 3 MUI of leucocyte IFNalpha three times a week)
Number of subjects: 42
Study 14733608 — intervention group
Group type: COMPARATOR
Intervention: IFNalpha alone (physiological solution followed by leucocyte IFNalpha three times a week for 6 months)
Number of subjects: 42
Study 11669086 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (20-40 mg/d)
Number of subjects: 0
Study 11669086 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 9520070 — intervention group
Group type: EXPERIMENTAL
Intervention: PSP cases (n=11)
Number of subjects: 20
Study 9520070 — intervention group
Group type: COMPARATOR
Intervention: Control diseases (Machado‐Joseph disease and DRPLA)
Number of subjects: 20
Study 9520070 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 20
Study 8209935 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective proximal vagotomy with ulcer excision
Number of subjects: 30
Study 8209935 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial gastrectomy with gastroduodenostomy
Number of subjects: 30
Study 2682926 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic neck dissection
Number of subjects: 0
Study 2682926 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic neck dissection
Number of subjects: 0
Study 1180024 — intervention group
Group type: EXPERIMENTAL
Intervention: Operated group (surgery)
Number of subjects: 280
Study 1180024 — intervention group
Group type: COMPARATOR
Intervention: Non-operated group (conservative treatment)
Number of subjects: 280
Study 1180024 — intervention group
Group type: COMPARATOR
Intervention: Doubtful group (random selection for surgery or not)
Number of subjects: 280
Study 31075442 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (2 L in divided doses)
Number of subjects: 40
Study 31075442 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg oral)
Number of subjects: 40
Study 31075442 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (in patients with LQTS)
Number of subjects: 40
Study 28545407 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon (CB) ablation
Number of subjects: 315
Study 28545407 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency (RF) ablation
Number of subjects: 315
Study 25921980 — intervention group
Group type: EXPERIMENTAL
Intervention: High depression scores
Number of subjects: 166
Study 25921980 — intervention group
Group type: COMPARATOR
Intervention: Low depression scores
Number of subjects: 166
Study 25921980 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression score
Number of subjects: 166
Study 25921980 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive problem orientation
Number of subjects: 166
Study 23575965 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide (600 μg or 900 μg) subcutaneously twice daily for 3 months
Number of subjects: 162
Study 23575965 — intervention group
Group type: EXPERIMENTAL
Intervention: CushingQOL questionnaire self-administered at baseline, month 3, month 6, and month 12
Number of subjects: 162
Study 21354671 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare education program (personalized information by a trained nurse and written leaflets)
Number of subjects: 996
Study 21354671 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 996
Study 19711606 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsonic toothbrush
Number of subjects: 0
Study 19711606 — intervention group
Group type: COMPARATOR
Intervention: Sonicare FlexCare toothbrush
Number of subjects: 0
Study 17403842 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.89 mg/kg over 10 days)
Number of subjects: 70
Study 17403842 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 70
Study 15372361 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (750 mg/day) for 6 months
Number of subjects: 16
Study 11182010 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 1500 microg/day
Number of subjects: 77
Study 11182010 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 1600 microg/day
Number of subjects: 77
Study 11182010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 9347208 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 800 micrograms self-administered vaginally 3 days after methotrexate
Number of subjects: 287
Study 9347208 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 800 micrograms self-administered vaginally 4 days after methotrexate
Number of subjects: 287
Study 9347208 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 800 micrograms self-administered vaginally 5 days after methotrexate
Number of subjects: 287
Study 9347208 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete abortion
Number of subjects: 287
Study 9347208 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure rate
Number of subjects: 287
Study 9347208 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects of methotrexate
Number of subjects: 287
Study 9347208 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects of misoprostol
Number of subjects: 287
Study 2285656 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin, 40 mg twice daily for 1 week
Number of subjects: 20
Study 2285656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7029370 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxin and PGF2 alpha
Number of subjects: 40
Study 7029370 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxin and Estradiol
Number of subjects: 40
Study 7029370 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol and PGF2 alpha
Number of subjects: 40
Study 7029370 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxin, Estradiol, and PGF2 alpha
Number of subjects: 40
Study 7029370 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxin and PGF2 alpha (in larger study)
Number of subjects: 40
Study 30642062 — intervention group
Group type: EXPERIMENTAL
Intervention: Taekwondo (TKD) intervention for one-and-a-half years
Number of subjects: 0
Study 27834560 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-heavy sled (80% body mass sled load)
Number of subjects: 16
Study 27834560 — intervention group
Group type: COMPARATOR
Intervention: Control group (unresisted sprints)
Number of subjects: 16
Study 24942813 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Power Program intervention
Number of subjects: 9
Study 24942813 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 9
Study 24559830 — intervention group
Group type: EXPERIMENTAL
Intervention: Cupping
Number of subjects: 12
Study 24559830 — intervention group
Group type: COMPARATOR
Intervention: Control (no cupping)
Number of subjects: 12
Study 22660805 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase 8 mg biweekly (twice monthly)
Number of subjects: 212
Study 22660805 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase 8 mg monthly (alternating with placebo)
Number of subjects: 212
Study 22660805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 20403617 — intervention group
Group type: EXPERIMENTAL
Intervention: Nightly intraurethral alprostadil
Number of subjects: 139
Study 20403617 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil citrate (50 mg)
Number of subjects: 139
Study 18832341 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy (0.16 mJ/mm(2); 2000 impulses)
Number of subjects: 245
Study 18832341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study 18832341 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy
Number of subjects: 245
Study 16027282 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy with or without concurrent chemotherapy
Number of subjects: 36
Study 11917241 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea in addition to stavudine (d4T) plus didanosine (ddI) and nevirapine (NVP)
Number of subjects: 24
Study 11917241 — intervention group
Group type: COMPARATOR
Intervention: No hydroxyurea, receiving stavudine (d4T) plus didanosine (ddI) and nevirapine (NVP)
Number of subjects: 24
Study 11917241 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 24
Study 11917241 — intervention group
Group type: COMPARATOR
Intervention: No hydroxyurea
Number of subjects: 24
Study 11917241 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (with and without hydroxyurea)
Number of subjects: 24
Study 10750519 — intervention group
Group type: EXPERIMENTAL
Intervention: Active health education
Number of subjects: 45
Study 10750519 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive health education
Number of subjects: 45
Study 10750519 — intervention group
Group type: COMPARATOR
Intervention: No education
Number of subjects: 45
Study 8624220 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline 1000 mg/d for 3 months
Number of subjects: 95
Study 8624220 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline 2000 mg/d for 2 months
Number of subjects: 95
Study 8624220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 1534249 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative megavoltage radiotherapy
Number of subjects: 0
Study 1534249 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 4030155 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 60
Study 4030155 — intervention group
Group type: COMPARATOR
Intervention: EMG biofeedback
Number of subjects: 60
Study 28964747 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour fasting group
Number of subjects: 276
Study 28964747 — intervention group
Group type: COMPARATOR
Intervention: 24-hour fasting group
Number of subjects: 276
Study 26456813 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 120
Study 26456813 — intervention group
Group type: COMPARATOR
Intervention: Standard supportive care
Number of subjects: 120
Study 25038431 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine (1.2 g, 2.4 g, or 4.8 g) once daily for 104 weeks
Number of subjects: 1182
Study 25038431 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 104 weeks
Number of subjects: 1182